| 1.22 -0.02 (-1.61%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.58 |
| Resists | First : | 1.79 | Second : | 2.21 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.12 | Second : | 0.94 |
| MAs | MA(5) : | 1.22 |
MA(20) : | 1.64 |
| MA(100) : | 1.99 |
MA(250) : | 1.97 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 5.7 |
| RSI | RSI(14): 28.2 |
|||
| 52-week | High : | 3.77 | Low : | 1.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DARE ] has closed above bottom band by 30.7%. Bollinger Bands are 70.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.28 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Thu, 30 Jul 2026
DARE|Dare Bioscience Inc|Price:1.230|Chg%:-0.010 - TradingKey
Wed, 29 Jul 2026
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tue, 28 Jul 2026
Women Exploring DARE to PLAY Can Now Reach Menopause Specialists - Stock Titan
Tue, 28 Jul 2026
Daré Bioscience Expands Access Options for DARE to PLAY™ - GlobeNewswire
Sun, 26 Jul 2026
Dare Bioscience Market Sentiment - Benzinga España
Tue, 21 Jul 2026
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.373e+007 (%) |
| Held by Institutions | 8.5 (%) |
| Shares Short | 716 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.96e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 967 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 1.16e+006 % |
| Gross Profit (p.s.) | 489.8 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 2.21569e+006 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 24.88 |
| Dividend | 0 |
| Forward Dividend | 601250 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|